Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

2021 Midyear Review: Non–Small-Cell Lung Cancer

Conference Correspondent  - AACR & ASCO 2021 - Midyear Review

Every year, researchers and clinicians report on exciting advancements in the diagnosis and treatment of cancer. In 2021, despite the COVID-19 pandemic, developments in the management of lung cancer continue to be important and intriguing.

Annual congresses, such as the American Association of Cancer Research (AACR) 2021 and the American Society of Clinical Oncology (ASCO) 2021, continue to be held via Internet-based video and audio links due to the COVID-19 pandemic. Despite this, hundreds of posters and presentations were shared.

Based on presentations from AACR and ASCO, here are some of the most important data that are likely to affect the care of patients with metastatic non–small-cell lung cancer in the months and years to come.

Related Items
Combination Therapies and New Molecular Targets—Presentations from AACR 2021
David Spigel, MD
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Combination of Nivolumab and Chemotherapy in Nonmetastatic Resectable NSCLC (CheckMate-816)
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Acquired Resistance Mutations After Treatment of EGFR-Mutated Metastatic NSCLC with Osimertinib plus Savolitinib (TATTON)
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Phase 3 Study of Tislelizumab Compared with Docetaxel in Advanced NSCLC (RATIONALE 303)
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Randomized Phase 3 Study of Sintilimab versus Docetaxel in Advanced Squamous NSCLC (ORIENT-3)
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Safety Results of Phase 2 Study of Bintrafusp plus Chemotherapy in Advanced NSCLC (INTR@PID LUNG 024)
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Phase 2 Study of Osimertinib + Oleclumab in Progressive T790M-Negative EGFR-Mutated NSCLC
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Phase 2 Study of D-0316 in Patients with Advanced NSCLC and EGFR T790M Mutation
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Phase 1 Trial of VS-6766, a Dual RAF-MEK Inhibitor, and Defactinib, an FAK Inhibitor
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Phase 2 Study of DM-CHOC-PEN in Patients with NSCLC with Central Nervous System Involvement
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.